MX354243B - Polipeptidos anticuerpos que antagonizan cd40. - Google Patents

Polipeptidos anticuerpos que antagonizan cd40.

Info

Publication number
MX354243B
MX354243B MX2013011966A MX2013011966A MX354243B MX 354243 B MX354243 B MX 354243B MX 2013011966 A MX2013011966 A MX 2013011966A MX 2013011966 A MX2013011966 A MX 2013011966A MX 354243 B MX354243 B MX 354243B
Authority
MX
Mexico
Prior art keywords
antibody polypeptides
sub
antagonize
polypeptides
antibody
Prior art date
Application number
MX2013011966A
Other languages
English (en)
Other versions
MX2013011966A (es
Inventor
Suri Anish
Sheriff Steven
Suchard Suzanne
Yamniuk Aaron
Krystek Stanley
Tamura James
Bryson James
Grant Steven
Drew Philip
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354243(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2013011966A publication Critical patent/MX2013011966A/es
Publication of MX354243B publication Critical patent/MX354243B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)

Abstract

La presente invención se refiere a los polipéptidos anticuerpos que se enlazan específicamente a un nuevo epítopo de CD40 humano. Los polipéptidos anticuerpos no muestran actividad agonista de CD40. Los polipéptidos anticuerpos son útiles en el tratamiento de trastornos que involucran la activación de CD40, tales como los trastornos autoinmunitarios. Los polipéptidos anticuerpos pueden ser anticuerpos de dominio (dAbs) que comprenden un dominio simple de VL o VH. La vida media de los polipéptidos anticuerpos puede ser incrementada por modificación de los polipéptidos anticuerpos para ser reactivos específicos dobles que pueden también reticularse a la albúmina sérica humana (HSA).
MX2013011966A 2011-04-21 2012-04-20 Polipeptidos anticuerpos que antagonizan cd40. MX354243B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477904P 2011-04-21 2011-04-21
PCT/US2012/034519 WO2012145673A1 (en) 2011-04-21 2012-04-20 Antibody polypeptides that antagonize cd40

Publications (2)

Publication Number Publication Date
MX2013011966A MX2013011966A (es) 2014-02-11
MX354243B true MX354243B (es) 2018-02-20

Family

ID=46000407

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011966A MX354243B (es) 2011-04-21 2012-04-20 Polipeptidos anticuerpos que antagonizan cd40.

Country Status (35)

Country Link
US (3) US9475879B2 (es)
EP (2) EP3372616A1 (es)
JP (2) JP6114256B2 (es)
KR (2) KR101905346B1 (es)
CN (2) CN106977604A (es)
AR (1) AR086360A1 (es)
AU (2) AU2012245309C1 (es)
BR (1) BR112013026828A2 (es)
CA (1) CA2833743A1 (es)
CL (1) CL2013003043A1 (es)
CO (1) CO6801649A2 (es)
CY (1) CY1120637T1 (es)
DK (1) DK2699601T3 (es)
EA (1) EA030851B1 (es)
ES (1) ES2664619T3 (es)
HR (1) HRP20180571T1 (es)
HU (1) HUE038848T2 (es)
IL (1) IL228720B (es)
LT (1) LT2699601T (es)
MA (1) MA35035B1 (es)
ME (1) ME03071B (es)
MX (1) MX354243B (es)
MY (1) MY165090A (es)
NO (1) NO2699601T3 (es)
PE (1) PE20141188A1 (es)
PH (1) PH12013502013B1 (es)
PL (1) PL2699601T3 (es)
PT (1) PT2699601T (es)
RS (1) RS57087B1 (es)
SG (1) SG194561A1 (es)
SI (1) SI2699601T1 (es)
SM (1) SMT201800228T1 (es)
TN (1) TN2013000417A1 (es)
TW (2) TW201245225A (es)
WO (1) WO2012145673A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2683406T3 (pl) 2011-03-11 2019-11-29 Beth Israel Deaconess Medical Ct Inc Przeciwciała anty-cd40 i ich zastosowania
PL2699601T3 (pl) 2011-04-21 2018-05-30 Bristol-Myers Squibb Company Polipeptydy przeciwciała, które antagonizują CD40
CN106928362B (zh) 2011-04-29 2021-10-26 埃派斯进有限公司 抗-cd40抗体及其使用方法
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
EP3113796A1 (en) * 2014-03-07 2017-01-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
MA41459A (fr) * 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3303402A4 (en) * 2015-05-27 2019-05-01 La Jolla Biologics, Inc. ANTIBODIES TO GLYPICAN-3 AND ITS USE TO CANCER DIAGNOSIS AND TREATMENT
HUE048284T2 (hu) 2015-05-29 2020-07-28 Abbvie Inc Anti-CD40 antitestek és alkalmazásuk
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
KR102019033B1 (ko) 2016-11-11 2019-09-06 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
EA201991207A1 (ru) 2016-12-19 2019-12-30 Гленмарк Фармасьютикалс С.А. Новые агонисты tnfr и их применение
MX2019011252A (es) * 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
US11384152B2 (en) 2017-05-24 2022-07-12 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
JP2020521458A (ja) * 2017-05-25 2020-07-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物
EP3630842A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
CN110267989B (zh) 2017-06-01 2023-04-04 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
CN112638375A (zh) 2018-06-15 2021-04-09 旗舰创业创新五公司 通过后细胞信号传导因子的调节来增加免疫活性
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN112969714B (zh) 2018-11-30 2022-11-22 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
BR112021010414A2 (pt) 2018-11-30 2021-09-08 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
JP2022519082A (ja) * 2019-02-01 2022-03-18 ラヴァ・セラピューティクス・ベー・フェー 新規ｃｄ４０結合抗体
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20210032356A1 (en) * 2019-08-02 2021-02-04 Eastern Virginia Medical School Method for treating seizures
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
MX2022007688A (es) 2019-12-20 2022-07-19 Amgen Inc Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11862306B1 (en) 2020-02-07 2024-01-02 Cvs Pharmacy, Inc. Customer health activity based system for secure communication and presentation of health information
CN115485301A (zh) * 2020-04-23 2022-12-16 阿尔法贝塔控股有限责任公司 治疗癌症的组合物和方法
WO2021236546A1 (en) 2020-05-18 2021-11-25 Bristol-Myers Squibb Company Antibody variants with improved pharmacokinetic properties
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
KR20250057233A (ko) 2023-10-20 2025-04-29 한상진 이동식 무선 자동 제습기
WO2025129007A1 (en) * 2023-12-15 2025-06-19 Werewool Inc. Soy alginate fibers
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU680102B2 (en) 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
IL125928A (en) 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
DE60143535D1 (de) * 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
KR101403910B1 (ko) * 2003-11-04 2014-06-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ４０ 단클론성 항체 및 그것의 사용 방법
DK1707627T3 (da) 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
SI1737962T1 (sl) 2004-03-24 2011-01-31 Domantis Ltd Univerzalni signalni peptid GAS1
CA2564296A1 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
ZA200702427B (en) * 2004-09-17 2008-12-31 Domantis Ltd Compositions monovalent for CD40L binding and methods of use
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
BRPI0611220A2 (pt) 2005-06-02 2010-08-24 Astrazeneca Ab anticorpos direcionados para cd20 e usos dos mesmos
WO2007133290A2 (en) * 2005-12-16 2007-11-22 Genentech, Inc. Anti-ox40l antibodies and methods using same
AU2007209202A1 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind IL-4 and/or IL-13
CN101426817B (zh) 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
MX2010011808A (es) * 2008-04-30 2011-03-04 Immunogen Inc Conjugados potentes y enlazadores hidrofilicos.
JP2012510468A (ja) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
AU2011235214B2 (en) 2010-03-31 2015-04-23 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
PL2699601T3 (pl) 2011-04-21 2018-05-30 Bristol-Myers Squibb Company Polipeptydy przeciwciała, które antagonizują CD40

Also Published As

Publication number Publication date
SI2699601T1 (en) 2018-04-30
SMT201800228T1 (it) 2018-07-17
ES2664619T3 (es) 2018-04-20
KR101734614B1 (ko) 2017-05-12
PE20141188A1 (es) 2014-09-22
CY1120637T1 (el) 2019-12-11
AU2016202672B2 (en) 2017-07-20
KR20170049628A (ko) 2017-05-10
CO6801649A2 (es) 2013-11-29
NO2699601T3 (es) 2018-06-16
CN106977604A (zh) 2017-07-25
CA2833743A1 (en) 2012-10-26
IL228720A0 (en) 2013-12-31
AU2012245309B2 (en) 2016-02-04
US20170015754A1 (en) 2017-01-19
US20140099317A1 (en) 2014-04-10
MX2013011966A (es) 2014-02-11
IL228720B (en) 2018-12-31
EP2699601A1 (en) 2014-02-26
SG194561A1 (en) 2013-12-30
CN103842382B (zh) 2017-03-15
AR086360A1 (es) 2013-12-11
EA201391564A1 (ru) 2014-02-28
ME03071B (me) 2019-01-20
MY165090A (en) 2018-02-28
US11136406B2 (en) 2021-10-05
HUE038848T2 (hu) 2018-11-28
EP2699601B1 (en) 2018-01-17
US10544228B2 (en) 2020-01-28
JP2014513953A (ja) 2014-06-19
HRP20180571T1 (hr) 2018-05-18
AU2012245309A1 (en) 2013-12-12
CL2013003043A1 (es) 2014-06-20
DK2699601T3 (en) 2018-04-23
PH12013502013B1 (en) 2018-11-28
NZ618025A (en) 2015-10-30
MA35035B1 (fr) 2014-04-03
AU2016202672A1 (en) 2016-05-26
TW201245225A (en) 2012-11-16
EA030851B1 (ru) 2018-10-31
TN2013000417A1 (en) 2015-03-30
LT2699601T (lt) 2018-03-26
KR101905346B1 (ko) 2018-10-05
US20200199244A1 (en) 2020-06-25
PT2699601T (pt) 2018-04-05
BR112013026828A2 (pt) 2016-11-29
PL2699601T3 (pl) 2018-05-30
JP6114256B2 (ja) 2017-04-12
AU2012245309C1 (en) 2016-07-21
KR20140009505A (ko) 2014-01-22
RS57087B1 (sr) 2018-06-29
TWI598363B (zh) 2017-09-11
TW201712038A (zh) 2017-04-01
US9475879B2 (en) 2016-10-25
CN103842382A (zh) 2014-06-04
JP2017099391A (ja) 2017-06-08
WO2012145673A1 (en) 2012-10-26
EP3372616A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
MX354243B (es) Polipeptidos anticuerpos que antagonizan cd40.
MX357231B (es) Polipeptidos de anticuerpos que antagonizan el ligando cd40 (cd40l).
NZ607969A (en) Cd33 binding agents
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
EA201400579A1 (ru) Антитела к il-36r
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
EP4509189A3 (en) Anti-fcrn antibodies
MX343858B (es) Anticuerpos anti-il-23.
NZ706751A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
EA201790309A1 (ru) Антитела к fap, способы их получения и применения
EP4310191A3 (en) Antigen-binding molecule containing modified fc region
EA201300978A1 (ru) Антитела к сеа
MX347020B (es) Anticuerpo contra el csf-1r.
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
SG195306A1 (en) Purification of biological products by constrained cohydration chromatography
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2013149111A3 (en) Anti-tlr4 antibodies and uses thereof
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
HK1198832A1 (en) Fn14 binding proteins and uses thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
MX343580B (es) Anticuerpos contra el g-csfr y sus usos.
SG10201901695RA (en) Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.

Legal Events

Date Code Title Description
FG Grant or registration